Abcam, ab267062, Human TRIM56 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TRIM56 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 2 bp deletion in exon 3. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 2 bp deletion in exon 3,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TRIM56, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRIM56 also known as Tripartite Motif Containing 56 or RNF109 is a protein involved in various cellular mechanisms. It weighs around 79 kDa and is expressed in many tissues including the spleen lymph nodes and lungs. TRIM56 contains a RING finger domain B-box motifs and a coiled-coil region which are typical features of the TRIM protein family. These domains suggest roles in ubiquitination and protein-protein interactions which are essential for its functions in signaling and regulatory processes.
Biological function summary
TRIM56 participates in immune regulation and antiviral defense. It acts as an interferon-stimulated gene product and does not appear to be part of a larger protein complex. Instead it induces antiviral states by mediating the innate immune response to viral infections. TRIM56 enhances the production of type I interferons by modifying the activation pathways. This function places TRIM56 as an immune defense agent which can restrict the replication of various viruses such as flaviviruses and coronaviruses therefore harboring significant implications in pathogen defense responses.
Pathways
TRIM56 integrates into the antiviral and innate immunity pathways. It prominently situates within the interferon signaling pathway enhancing the body's defense through the upregulation of interferon production. TRIM56 interacts with several proteins in these pathways including STING and MAVS which are known to be important mediators in the recognition of viral presence. Through these interactions TRIM56 facilitates the activation of downstream signaling cascades leading to the expression of interferon-stimulated genes.
TRIM56 exhibits significant connections to viral infections and autoimmune diseases. Its role in antiviral responses implicates it in diseases like hepatitis C as it can suppress viral replication. Although TRIM56 aids in defending against infections its dysregulation may also link to autoimmune conditions where its interaction with proteins such as IFNAR1 can result in excessive immune responses leading to tissue damage and inflammation. Such dual roles highlight TRIM56 as an important regulator in both protective and pathological immune responses.